We have a robust and growing patent portfolio covering our proprietary GalXC™ RNAi platform and other RNAi gene targeting technologies.
Our global patent estate, excluding patents and patent applications we have licensed, includes more than 65 worldwide issued patents or allowed patent applications and more than 130 pending patent applications in more than 40Xổ số miền nam và miền bắc different patent families, each family representing a different aspect of our technology. Together, these patent estates protect the scientific and commercial development of our RNAi molecules and associated delivery technologies.
Xổ số miền nam và miền bắcOur activities in the intellectual property space focus on two areas:
Specific gene targets
Dicerna’s gene-targeting intellectual property provides us with a precise and long-lasting way to knock down specific disease-causing protein production. First recognized over 20 years ago, the concept of RNA interference targeting came from studies on the nematode Caenorhabditis elegans. Today our structural approach utilizes Dicer substrate short interfering RNA, or DsiRNA, to achieve our therapeutic goals. Our gene targets in this space include our proprietary primary hyperoxaluria (PH) program and its focus on the lactate dehydrogenase gene, our alpha-1 antitrypsin (A1AT) liver-associated disease program and numerous other gene targets with our collaborators.
In this space we have extensive patent coverage including U.S. patent numbers:
Xổ số miền nam và miền bắcFrom this foundation, we have continued to innovate the design, durability and potency of our DsiRNA constructs.
GalXC technology platform
Xổ số miền nam và miền bắcAlong with targeting specific genes, Dicerna invented the GalXC RNAi technology platform, which enhances the Company’s DsiRNA constructs and improves their ability to safely deliver RNAi therapies that are specific and potent in the way they target disease. We continue to expand the utility of our GalXC platform through a variety of modifications and chemistries. Given their structure, our RNAs provide a long duration of action, have a high target specificity and have a high therapeutic index.
These compounds include DsiRNAs that have a chemically attached component for targeting, making them:
- Highly efficient in accessing the desired tissue.
- Suitable for administration via a simple injection under the skin.
The delivery/targeting vehicle is directly attached, or conjugated, to the RNAi molecule created with our GalXC technology.
Xổ số miền nam và miền bắcWe are using our proprietary GalXC platform to advance the development of next-generation RNAi-based therapies designed to silence disease-driving genes in the liver and other organ systems, including neural tissues, to address a broad range of other diseases.
